Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis Clinical Trial

Official title:

Phase III Trial of Tetrathiomolybdate (TM) in Primary Biliary Cirrhosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00805805
• Other study ID #: PBC
• Status: Completed
• Phase: Phase 3
• First received: December 8, 2008
• Last updated: May 19, 2017
• Start date: April 2006
• Est. completion date: December 2008

Study information

• Verified date: May 2017
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The University of Michigan is conducting a study investigating a potential new treatment aimed at slowing/halting progression of primary biliary cirrhosis. This will be a 2 arm double blind study in which half of the patients will be randomly selected to receive a placebo (capsule with no active ingredient) and half will receive the new treatment drug, tetrathiomolybdate. Neither the patient nor the treating physician will know which arm the patient is in. The length of the study for each patient is 24 months of drug therapy. Lab draws will be necessary weekly for the first 6 weeks of the study, followed by every other week for 3 weeks, and then monthly for the remainder of the 2 year period. In addition, intermittent history and physicals and urine samples will also be necessary. There is no cost to you for any experimental treatment. All patients in both arms will continue on ursodiol and receive standard of care treatment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Generally medically healthy

• Age 18 and older

• Documented primary biliary cirrhosis

• Alkaline phosphatase > 137

Exclusion Criteria:

• Severe liver decompensation

• Requirement for renal dialysis

• Pregnancy or nursing

• Meld score > 15 (13-15 will require a physician's clinical judgment)

• Uncontrolled congestive heart failure

• Severe diabetic neuropathy

• Severe pulmonary disease

• Advanced cancer

• Requirement for steroid therapy

• Uncontrolled ascites, variceal hemorrhage or spontaneous bacterial peritonitis

• Pregnant or nursing

Related Conditions & MeSH terms

• Fibrosis
• Liver Cirrhosis
• Liver Cirrhosis, Biliary
• Primary Biliary Cirrhosis

Intervention

Drug:
• Tetrathiomolybdate
120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).

Other:
• Placebo
Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
George Brewer	FDA Office of Orphan Products Development

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in drug treated group vs placebo group in two liver function tests and one serum cytokine measurement		2 years
Secondary	Improvement in drug treated group vs placebo group in serum CRP or interleukin-1-beta-levels		2 years